Cutler Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Cutler Group’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-32,400	Closed	-$62K	–	6025
2017 Q3	$62K	Buy	+32,400	New	+$542K	﹤0.01%	2051
2017 Q1	–	Sell	-7,800	Closed	-$4K	–	7287
2016 Q4	$4K	Buy	7,800 +3,400	+77%	+$54.7K	﹤0.01%	5156
2016 Q3	$14K	Buy	+4,400	New	+$59.2K	﹤0.01%	3826
2016 Q2	–	Sell	-8,300	Closed	-$4K	–	7362
2016 Q1	$4K	Buy	+8,300	New	+$68.1K	﹤0.01%	5104

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Cutler Group's VNDA Position: Q1 2022 in Review

Cutler Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2022, closing a stake of 6,250 shares — an estimated $98K sold.

Cutler Group first reported a position in VNDA in Q4 2015 and held it in 8 quarters. The position peaked at $274K in Q3 2016. 188 funds tracked by Wall St. Rank hold VNDA as of Q1 2022.

Cutler Group reported no remaining Vanda Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Cutler Group sold 6,250 Vanda Pharmaceuticals shares in Q1 2022, an estimated $98K.
Cutler Group first reported a position in Vanda Pharmaceuticals in Q4 2015 and held it in 8 quarters.
Cutler Group's Vanda Pharmaceuticals position peaked at $274K in Q3 2016.
188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.